BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics by Phipps, Amanda I. et al.
BRAF mutation status and survival after colorectal cancer
diagnosis according to patient and tumor characteristics
Amanda I. Phipps1, Daniel D. Buchanan2, Karen W. Makar1, Andrea N. Burnett-Hartman1,
Anna E. Coghill1, Michael N. Passarelli1, John A. Baron3, Dennis J. Ahnen4, Aung Ko Win5,
John D. Potter1,6, and Polly A. Newcomb1
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
2Familial Cancer Laboratory, Queensland Institute for Medical Research, Brisbane, QLD,
Australia 3Department of Medicine, University of North Carolina, Chapel Hill, NC, USA 4Denver
Veterans Affairs Medical Center, University of Colorado School of Medicine, Denver, CO, USA
5Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of
Melbourne, Parkville, VIC, Australia 6Centre for Public Health Research, Massey University,
Wellington, New Zealand
Abstract
BACKGROUND—BRAF mutations in colorectal cancer (CRC) are disproportionately observed
in tumors exhibiting microsatellite instability (MSI), and are associated with other prognostic
factors. The independent association between BRAF-mutation status and CRC survival, however,
remains unclear.
METHODS—We evaluated the association between the BRAF c.1799T>A (p.V600E) mutation
and survival in individuals with incident invasive CRC diagnosed between 1997 and 2007 in
Western Washington State. Tumor specimens were tested for this BRAF mutation and MSI status.
We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the
association between BRAF-mutation status and disease-specific and overall survival. Stratified
analyses were conducted by age, sex, tumor site, stage, and MSI status.
RESULTS—Among 1,980 cases tested, 12% were BRAF c.1799T>A (p.V600E) mutation-
positive (N=247). BRAF-mutated CRC was associated with poorer disease-specific survival
adjusting for age, sex, time from diagnosis to enrollment, stage, and MSI status (HR=1.43, 95%
CI: 1.05–1.95). This association was limited to cases diagnosed at ages <50 (HR=3.06, 95% CI:
1.70–5.52), and was not evident in cases with MSI-high tumors (HR=0.94, 95% CI: 0.44–2.03).
Associations with overall survival were similar.
CONCLUSIONS—Our results show that the prevalence of BRAF mutations in CRC differs by
patient and tumor characteristics, and suggest that the association between BRAF status and CRC
survival may differ by some of these factors.
IMPACT—The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with
significantly poorer prognosis after CRC diagnosis among subgroups of patients.
Keywords
colorectal cancer; BRAF; survival; mortality; microsatellite instability
Corresponding author: Amanda Phipps, 1100 Fairview Ave. N., M4-B402, Seattle, WA 98109-1024, telephone: (206)667-7741,
fax: (206)667-7850, aphipps@fhcrc.org.
Conflicts of interest: None to report.
NIH Public Access
Author Manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2013 October 01.
Published in final edited form as:















Somatic mutations in BRAF, a proto-oncogene involved in the RAS-RAF-MAPK pathway,
are observed in 10–20% of colorectal cancers (CRCs) (1–5). The BRAF c.1799T>A
(p.V600E) mutation accounts for approximately 90% of such mutations (6, 7) and results in
constitutive activation of BRAF kinase. Recent studies have suggested that this somatic
mutation is associated with poorer survival after CRC diagnosis (1, 2, 8–13), and may
impact response to certain treatment regimens (9, 14–16). Prior studies have also
demonstrated that BRAF-mutation status is strongly associated with other CRC prognostic
factors, most notably the presence of high microsatellite instability (MSI-H) (1, 2, 8–10, 12,
13, 17–19) as is mediated by the relationship between BRAF-mutation status and CpG
island methylation (20).
Despite the fact that BRAF mutations are more common in MSI-H CRC, which is associated
with better survival than CRC exhibiting microsatellite stability (MSS) (2, 8, 13, 21), BRAF
mutations paradoxically appear to be associated with a poorer CRC prognosis. The few
studies that have evaluated BRAF-mutation status and MSI status in combination have been
limited by small numbers and inconsistent in their findings (1, 2, 8, 10–13). Ogino et al.
recently reported that, in a clinical trial of stage III colon cancer, overall survival was similar
in patients with BRAF-wildtype / MSS and BRAF-mutated / MSI-H disease, comparatively
better in patients with BRAF-wildtype / MSI-H disease, and poorer in those with BRAF-
mutated / MSS disease (12); however, associations with survival in this small study (n=506)
did not attain statistical significance and require further evaluation.
We used data from two concurrent population-based studies of incident invasive CRC
conducted in Western Washington State to further evaluate the relationship between BRAF
c.1799T>A (p.V600E) mutation status and survival after CRC diagnosis, both overall and
among subsets defined by other tumor and patient characteristics.
METHODS AND MATERIALS
Study Population
Details of the studies included here have been published elsewhere (22, 23). Briefly, eligible
participants included men and women diagnosed with incident invasive CRC between
January 1998 and June 2002 who, at the time of diagnosis, were aged 20–74 years and
resided in King, Pierce, or Snohomish counties in Western Washington State. Over this
same period, we recruited women diagnosed with invasive CRC between ages 50–74
residing in 10 additional surrounding counties. During a second phase of study recruitment,
we identified eligible participants as individuals with invasive CRC in this broader
ascertainment area (i.e., 13 Washington State counties) who were diagnosed at younger ages
(i.e., 18–49 years) between April 2002 and July 2007. All cases were identified via the
population-based Surveillance, Epidemiology, and End Results (SEER) cancer registry
serving Western Washington State. Eligibility was limited to English speakers with publicly
available telephone numbers. Of 3,585 individuals contacted and identified as eligible, 463
(13%) were deceased, 351 (10%) refused participation, 128 (4%) were lost to follow-up
before interview, and 24 (0.7%) completed only a partial interview. Adequate tumor
specimens were available for 78% (N=2120) of enrolled participants who completed the
interview (N=2708).
All participants completed a structured telephone interview at enrollment. Interviews were
conducted an average of 8.6 months after diagnosis (range=2.6–32.7 months). Participants
were asked to provide detailed information on exposures occurring at least 2 years pre-
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diagnosis, including smoking history, alcohol consumption, family history of CRC,
demographic factors, history of CRC screening, and use of selected medications.
Vital status was determined through linkage to SEER and the National Death Index.
Through these sources, we obtained information on the date and cause of death, classified
according to ICD-10 conventions (24). Disease-specific deaths included those with an
underlying cause attributed to ICD-10 codes C18.0-C20.0 or C26.0. Vital status linkage was
performed periodically, with the most recent linkage capturing deaths occurring through
September 2010.
This study was approved by the Institutional Review Board of the Fred Hutchinson Cancer
Research Center in accordance with assurances filed with and approved by the U.S.
Department of Health and Human Services.
Tumor characteristics
DNA was extracted from paraffin-embedded formalin-fixed tumor tissue. Extracted DNA
was tested for the c.1799T>A (p.V600E) BRAF mutation (N=2006) using a fluorescent
allele-specific PCR assay as described previously (25). Cases for whom BRAF-mutation
status was found to be equivocal (N=2) or for whom testing failed (N=24) were excluded
from the analysis.
For most cases, MSI status was determined via testing on a 10-gene panel in tumor DNA
and DNA from normal surrounding tissue (BAT25, BAT26, BAT40, MYCL, D5S346,
D17S250, ACTC, D18S55, D10S197, and BAT34C4) as previously described (N=1430)
(23, 26). Briefly, tumors were classified as MSI-H if instability was observed for ≥30% of
markers, and as MSS if instability was observed in <30% of markers. For cases tested in
later years of the study (N=470), MSI status was based on immunohistochemistry testing of
four markers: MLH1, MSH2, MSH6, and PMS2 (27, 28). Cases whose tissue exhibited
positive staining for all markers were considered MSS; cases negative for at least one
marker were considered MSI-H. Cases for whom test results were equivocal or for whom
testing was not completed (N=80) were classified as having unknown MSI status.
Tumor site and stage at diagnosis information was available from SEER. Tumors located in
the cecum to splenic flexure were grouped together as proximal colon cancers (ICD-O-3
codes C180, C182-C185) (29). Tumors in the descending (C186) and sigmoid colon (C187)
were classified as distal colon cancers, and tumors in the rectosigmoid junction (C199) and
rectum (C209) were grouped together as rectal cancers. Stage at diagnosis was recorded
according to SEER summary staging conventions (localized, regional, distant stage) (30).
Statistical analysis
We used Cox regression to evaluate the association between BRAF c.1799T>A (p.V600E)
mutation status and survival after CRC diagnosis, where the time axis was defined as days
since diagnosis. We conducted separate analyses for disease-specific and overall survival. In
analyses of disease-specific survival, persons who died due to causes other than CRC were
censored at the time of death. In all analyses, participants still alive at their last vital status
assessment were censored at that date. We evaluated associations between BRAF-mutation
status and survival outcomes in the full cohort and within strata defined by patient
characteristics (age at diagnosis, sex) and tumor characteristics (tumor site, stage, MSI
status). Proportional hazards assumptions were assessed by testing for a non-zero slope of
the scaled Schoenfeld residuals on ranked failure times (31).
Regression models included adjustment terms for age (five-year categories), time from
diagnosis to interview (<6, 6–9, >9 months), and sex. We also assessed confounding by a
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series of patient and tumor characteristics: cigarette smoking (never, former, current), body
mass index (BMI) (<25.0, 25.0–29.9, ≥30.0 kilograms/meters2), tumor site (proximal colon,
distal colon/rectum), stage (localized, regional, distant), MSI status (MSS, MSI-H). Of these
additional factors, only stage and MSI status were retained in our final analytic model as
adjustment for other variables had minimal impact on effect estimates (<5% change).
To account for missing MSI data in cases with known BRAF-mutation status, we used an
iterative multiple imputation model for the prediction of unknown MSI status. Our
imputation model included all covariate variables from the multivariate model, as well as
family history of CRC, tumor site, BMI, smoking history, race, survival time, and the
survival outcome of interest (32–34). All analyses were conducted in STATA SE version
12.0 (College Park, Texas).
RESULTS
Over study follow-up (median=7.4 years, range=0.4–13.8 years), 38% of enrolled cases died
(i.e., 62% overall survival), of whom 62% died due to CRC. Characteristics of the study
population are presented by BRAF-mutation status in Table 1. BRAF c.1799T>A (p.V600E)
mutations were evident in 12% of cases (i.e., BRAF-mutated). Cases with BRAF-mutated
CRC tended to be older at diagnosis than cases without a BRAF c.1799T>A (p.V600E)
mutation (i.e., BRAF-wildtype) and were more likely to be female, to have MSI-H tumors,
and to have tumors located in the proximal colon (p<0.001). The prevalence of BRAF
mutations increased across subsites from the rectum (2%) to ascending colon (30%). BRAF-
mutated cases were also less likely to have distant-stage disease at diagnosis (p=0.008).
In unadjusted analyses, there was no difference in disease-specific or overall survival for
BRAF-mutated vs. wildtype cases (Table 2). However, after multivariable-adjustment, the
presence of a BRAF c.1799T>A (p.V600E) mutation was associated with statistically
significantly poorer disease-specific survival (HR=1.43, 95% CI: 1.05–1.95); adjustment for
stage and MSI status had the greatest impact on point estimates. Stratified analyses indicated
statistically significant heterogeneity in the association between BRAF-mutation status and
survival by age at diagnosis (pinteraction<0.001 and 0.04 for disease-specific and overall
survival, respectively). The adjusted association between BRAF-mutation status and
survival was strongest in cases aged <50 at diagnosis (HR=3.06, 95% CI: 1.70–5.52 and
HR=2.12, 95% CI: 1.20–3.76, for disease-specific and overall survival, respectively), with
little evidence of an association in cases diagnosed at ages ≥50. The adjusted association
with BRAF-mutation status also appeared stronger in cases with regional or distant-stage
CRC, particularly in analyses of disease-specific survival (pinteraction=0.07). There was no
heterogeneity in associations by sex or tumor site. Interaction by MSI status was not
statistically significant (pinteraction=0.17 and 0.85 for disease-specific and overall survival,
respectively); however, the presence of a BRAF c.1799T>A (p.V600E) mutation was
associated with significantly poorer disease-specific survival for cases with MSS disease
(HR=1.62, 95% CI: 1.16–2.26) but not for cases with MSI-H disease (HR=0.94, 95% CI:
0.44–2.03).
When we evaluated the association between joint BRAF / MSI status and survival we found
that, relative to cases with BRAF-wildtype / MSS disease, cases BRAF-mutated / MSS CRC
experienced the poorest disease-specific survival (HR=1.60, 95% CI: 1.14–2.23) (Table 3).
Cases with MSI-H disease experienced more favorable disease-specific survival, regardless
of BRAF c.1799T>A (p.V600E) mutation status. This pattern was attenuated in analyses of
overall survival, but results continued to suggest that cases with BRAF-mutated / MSS
disease experienced the poorest survival. Analyses excluding cases with unknown MSI
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status (i.e., not using multiple imputation to account for unknown MSI status) yielded
almost identical results (Supplementary Tables 1–2).
Enrolled cases for whom BRAF-mutation status was unknown (N=728) were younger at
diagnosis than cases with known mutation status, and more likely to have distant-stage
disease, and to have rectal cancer; however, survival did not differ in enrolled cases with
unknown versus known BRAF-mutation status (HR=0.99, 95% CI: 0.65–1.51 and HR=0.92,
95% CI: 0.65–1.31 for disease-specific and overall survival, respectively) (data not shown).
DISCUSSION
In this cohort of men and women with incident invasive CRC, we found that individuals
with tumors exhibiting the BRAF c.1799T>A (p.V600E) mutation were significantly more
likely to die from their disease than individuals without this mutation. This association was
most evident in individuals diagnosed before age 50. Although there was no significant
interaction by MSI status, the association between BRAF-mutation status and disease-
specific survival was evident only among those with MSS CRC. Cases with BRAF-
mutated / MSS CRC had the poorest prognosis across case groups defined by joint BRAF-
mutation / MSI status. Associations with overall survival were more modest than
associations with disease-specific survival.
Previous studies have similarly reported that BRAF-mutated CRC is associated with poorer
prognosis than BRAF-wildtype disease (1, 2, 10–13, 35). Most recently, Kalady et al.
reported that the presence of a somatic BRAF mutation was associated with a 1.79-fold
(95% CI: 1.05–3.05) increased risk of all-cause mortality in patients with stage I-III CRC
(13). Other studies have noted even stronger associations between BRAF-mutation status
and survival (1, 10–12, 18, 35), particularly with respect to disease-specific survival (1, 2,
35).
Given the association between BRAF-mutation status and MSI (1, 2, 8, 10–13, 17, 19), and
the well-established prognostic value of MSI status (21), it is important to consider MSI
when evaluating the relationship between BRAF status and survival. Here, we found that the
adverse association between the presence of a BRAF c.1799T>A (p.V600E) mutation and
CRC survival was evident only in individuals with MSS CRC, although interaction by MSI
status was not significant. Some previous, small studies have noted that the association
between BRAF-mutation status and survival is more pronounced in, if not restricted to,
patients with MSS CRC (10, 11, 18, 35). Using data from a phase III clinical trial of stage
III colon cancer, Ogino et al. recently reported that patients with BRAF-mutated / MSS
tumors had the poorest recurrence-free, disease-free, and overall survival, whereas survival
was most favorable in patients with BRAF-wildtype / MSI-H disease, and intermediate in
patients with BRAF-wildtype / MSS or BRAF-mutated / MSI-H disease (12). Studies in
patients with MSS CRC have also reported that the BRAF c.1799T>A (p.V600E) mutation
is independently associated with poorer survival (1, 36). In a recent analysis of patients with
proximal colon cancers exhibiting proficient DNA mismatch repair (i.e., MSS), Pai et al.
noted that the presence of a BRAF-mutation was associated with distinct clinical,
pathologic, and molecular features, including: more frequent lymphatic invasion, lymph
node metastasis, mucinous histology, signet ring histology, and high tumor budding. These
aggressive features could contribute to a poorer prognosis. In contrast, other studies have
reported that BRAF-mutation status is more informative of CRC prognosis in MSI-H cases
(2, 8, 13). The basis for such inconsistencies is unclear, but may be related to sample size
limitations. Given that testing for MSI and BRAF-mutation status is becoming increasingly
routine clinical practice for distinguishing Lynch Syndrome and sporadic cases, and for
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guiding treatment approaches (37), it is important to understand the relationship between
these markers and CRC prognosis.
Although the presence of a somatic BRAF c.1799T>A (p.V600E) mutation appears to be
independently associated with shorter disease-specific survival, several characteristics
typical of BRAF-mutated CRC are also associated with prognosis. In particular, BRAF
mutations are more prevalent among CRC patients diagnosed at an advanced age (12, 13,
18) and patients with proximal colon cancer (11–13, 17–19). With respect to tumor site,
Yamauchi et al. recently demonstrated an increase in the frequency of BRAF mutations
along colorectum subsites from the rectum to ascending colon (5); this pattern was evident
in our data, lending support to the theory of a CRC continuum (38). The frequency of MSI-
H follows a similar pattern and is highly correlated with the presence of a BRAF mutation
(2, 10–13, 17, 18, 39). Although the age and tumor site distribution associated with BRAF-
mutated CRC may be expected to confer poorer overall and disease-specific survival,
respectively, the fact that patients with BRAF-mutated CRC are more likely to have MSI-H
tumors could be considered prognostically favorable. Consistent with some degree of
balancing out of these potentially prognostic attributes, we observed that BRAF c.1799T>A
(p.V600E) mutation status was not associated with survival in the absence of multivariate
adjustment. Instead, the association between BRAF-mutation status and poorer disease-
specific survival appeared to be most pronounced among those groups of cases among
whom BRAF mutations are less common (i.e., cases aged <50 at diagnosis or with MSS).
These results highlight the need to consider the association between BRAF-mutation status
and CRC survival in the context of potential modifying factors. Our findings also support
the argument that mutated BRAF is on the causal pathway to poorer survival, inasmuch as it
is not only directly associated with poorer outcomes, but also has greater impact when it
occurs in the absence of its usual biologic and patient-characteristic correlates.
Findings presented here should be interpreted in the context of study limitations. In the
absence of treatment information, we were unable to assess possible treatment interactions
with BRAF-mutation status; however, although there is some suggestion that response to
EGFR inhibitors is more favorable in individuals with BRAF-wildtype CRC (9), studies
have noted no significant differences in response to standard chemotherapy regimens by
BRAF-mutation status (12, 19, 40). We also did not test for BRAF mutations other than c.
1799T>A (p.V600E). It is plausible that other BRAF mutations with effects on BRAF
kinase activity could be associated with CRC survival. In light of the rarity of other BRAF
mutations, however, it is unlikely that information regarding such mutations would alter our
findings. Additionally, BRAF c.1799T>A (p.V600E) mutation status was not determined in
27% of enrolled cases, nor was it determined in cases who were eligible for the study but
were not enrolled. It is plausible that the distribution of BRAF-mutation status could differ
among cases excluded from the present analysis due to missing data. In particular, if BRAF-
mutated CRC is truly associated with poorer prognosis, one might expect the prevalence of
BRAF mutations to have been higher in cases who died before they could be enrolled.
Exclusion of such cases could have attenuated our effect estimates, although the extent and
impact of survivor bias is unknowable.. We also lacked information on the CpG island
methylation phenotype (CIMP) status of tumors, which is highly correlated with BRAF-
mutation status (1, 2, 35, 39, 41). Promoter methylation of MLH1, as part of CIMP, is a
principal cause of MSI in sporadic CRC, thus constituting a link between BRAF-mutation
status and MSI (42–45). The presence of MSI in the absence of CIMP and a BRAF mutation
may be indicative of Lynch Syndrome-associated CRC (43), which has been associated with
better prognosis (46). BRAF-mutated / MSI-H and BRAF-mutated / MSS CRC are both
thought to develop along the so-called serrated pathway (42, 43) with epigenetic inactivation
of a different panel of genes. Although we did not have information on CIMP, our results
are suggestive of a poorer prognosis associated with the BRAF-mutated / MSS phenotype.
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There are also several important strengths of this analysis. The population-based design of
the cohort contributes to the generalizability of our results. Well-annotated, existing cohorts
such as the one used here represent an important resource for informing cancer research (47,
48). The availability of detailed information on tumor and patient characteristics allowed us
to efficiently evaluate of potential sources of heterogeneity in the association between
BRAF-mutation status and survival.
In conclusion, in this large prospective study, the presence of a somatic BRAF c.1799T>A
(p.V600E) mutation was independently associated with poorer CRC survival. Our data are
consistent with previous reports that the prevalence of BRAF mutations in CRC differs by
age at diagnosis, tumor site, and MSI status, and suggest that the association between BRAF
status and survival may differ according to some of these characteristics. Future studies
should explore the potential mechanisms responsible for these observed associations, and
further describe the features of BRAF-mutated CRC that may contribute to disease
progression and prognosis.
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TABLE 1
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      Descending colon
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   Rectal:
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% distribution excludes cases with unknown value of characteristic
c
p-value for chi-square of proximal / distal / rectal tumor site distribution
d
p-value for chi-square of tumor subsite distribution (e.g., cecum, ascending colon, hepatic flexure etc)
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TABLE 3
Joint BRAF / MSI status and survival after colorectal cancer diagnosis
Disease-Specific Survival Overall Survival
Deaths / Cases HR (95% CI)a Deaths / Cases HR (95% CI)a
BRAF-wildtype / MSS 375/1494 1.00 (ref) 581/1494 1.00 (ref)
BRAF-wildtype / MSI-H 22/171 0.60 (0.39–0.93) 49/171 0.84 (0.62–1.12)
BRAF-mutated / MSS 38/109 1.60 (1.14–2.23) 49/109 1.24 (0.92–1.66)
BRAF-mutated / MSI-H 14/126 0.57 (0.33–0.98) 51/126 0.99 (0.73–1.33)
a
Adjusted for age at diagnosis, sex, time from diagnosis to enrollment, and stage.
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